Author name: DrugChatter

Why Pharmaceutical Brands Must Shift from Social Listening to AI Monitoring — Before Regulators Do The clinical detail rep used […]

How large language models are quietly reshaping brand exposure, regulatory liability, and the future of pharmacovigilance The alert came from

How pharmaceutical brands are losing control of patient conversations, clinical narratives, and competitive positioning inside the black box of generative

How pharmaceutical companies are using AI surveillance tools to protect brand integrity, stay ahead of the FDA, and decode what

Walk into any pharmaceutical brand team meeting in 2025 and you’ll hear the same anxieties: biosimilar erosion, payer step therapy,

The pharmacovigilance team at a mid-size specialty pharma company discovered the problem during a routine brand audit. Patients searching for

Drug companies spend billions crafting brand narratives. AI is rewriting them in real time — and most manufacturers have no

A scan of patient-generated questions reveals a striking pattern: confusion rarely centers on what drugs do—it centers on how they

How artificial intelligence is tracking, shaping, and sometimes undermining pharmaceutical brand strategy — and what drug companies need to do

A scan of hundreds of real-world questions on DrugChatter reveals a consistent pattern: patients are not just asking what a

In online drug discussions, some of the most routine-sounding questions can mask a more serious issue: patients delaying appropriate medical

Patients aren’t just looking up side effects anymore—they’re making real-time treatment decisions based on fragmented, crowd-sourced advice. A review of